Bluestar Genomics Presents Positive Results of its Pancreatic Cancer Test Performance Evaluation at 2022 ASCO GI Cancers Symposium

SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced positive performance evaluation study results for its pancreatic cancer test. These data confirm that its pancreatic cancer test detects the disease with 55.2% sensitivity and 98.4% specificity in patients with and without diabetes. Th
Click here to view original post